SAT0002 Baseline Serum OPG but not Trail Predicts Remission in Early Arthritis: Results from the French Espoir Cohort

SAT0002 Baseline Serum OPG but not Trail Predicts Remission in Early Arthritis: Results from the French Espoir Cohort

Background TNF-Related Apoptosis Inducing Ligand (TRAIL) is a member of the TNF familly. Osteoprotegerin (OPG) is a soluble receptor of TRAIL that also inhibits Receptor activator of nuclear factor kappa-B ligand (RANKL). We previously reported that, in a cohort of early arthritis(< 2 years), a h...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2013-06, Vol.72 (Suppl 3), p.A579-A579
Hauptverfasser: Audo, R., Daien, C., Papon, L., Lukas, C., Hahne, M., Combe, B., Morel, J.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background TNF-Related Apoptosis Inducing Ligand (TRAIL) is a member of the TNF familly. Osteoprotegerin (OPG) is a soluble receptor of TRAIL that also inhibits Receptor activator of nuclear factor kappa-B ligand (RANKL). We previously reported that, in a cohort of early arthritis(< 2 years), a high TRAIL/OPG ratio at baseline was associated with remission (DAS28
ISSN:0003-4967
1468-2060
DOI:10.1136/annrheumdis-2013-eular.1728